Long Zheng, M.D., Ph.D.
Professor, Pathology and Laboratory Medicine
Department Chair, University of Kansas Medical Center , Pathology and Laboratory Medicinexzheng2@kumc.edu
Dr. Zheng is Russell J. Eilers MD Endowed Professor and Department Chair of Pathology and Laboratory Medicine at The University of Kansas Medical Center. Dr. Zheng completed his medical degree at Nanchang University, China and PhD at University of Vienna, Austria. Following his residency in Pathology and fellowship in Transfusion Medicine and Hemostasis at Washington University in St. Louis, Missouri, Dr. Zheng took his first faculty position at the University of Pennsylvania, Philadelphia, PA. He quickly rose to the rank of a tenured Associate Professor. Dr. Zheng was then recruited to the University of Alabama at Birmingham where he served the Division Director of Laboratory Medicine and attended transfusion medicine and coagulation service. In early 2020, Dr. Zheng was named the chair and service chief in the Department of Pathology and Laboratory Medicine, the University of Kansas Medical Center, Kansas City, Kansas.
Dr. Zheng's research focuses on understanding the pathogenesis of thrombotic thrombocytopenic purpura (TTP), a potentially fatal blood disorder. Dr. Zheng and his colleagues have published more than 125 manuscripts in high-profile journals and 6 highly sought book chapters. Dr. Zheng is the standing member of Hemostasis, Thrombosis, and Blood Transfusion (HTBT) study section at NIH, served associate editor for Journal of Thrombosis and Haemostasis, and continues to serve the associate or section editor in Archives of Pathology and Laboratory Medicine, Annals of Blood, Journal of Clinical Medicine, and Genomics. Dr. Zheng has mentored several dozen of trainees including medical and graduate students, postdoctoral fellows, junior faculty, and physician scientists.
Education and Training
- MD, Medicine, Nanchang University, Nanchang, Jiangxi
- PhD, Mol. Cell Biology, University of Vienna, Vienna, Austria
- Residency, Pathology, Washington University , St. Louis , Missouri
- Clinical Fellowship, Transfusion Medicine and Hemostasis, Washington University, St. Louis, Missouri
Licensure, Accreditations & Certifications
- Medical Liscence , Kansas State Board of Healing Arts
Dr. Zheng's laboratory has been interested in studying the mechanism of normal and abnormal blood coagulation, specifically the pathogenesis and novel therapeutics of immune thrombotic thrombocytopenic purpura (iTTP). Severe deficiency of plasma metalloprotease ADAMTS13 is the important cause of iTTP. ADAMTS13 cleaves endothelial von Willebrand factor (VWF), critical for normal hemostasis. An inability to cleave VWF results in uncontrolled platelet agglutination and thrombus formation throughout the body.
Following are Dr. Zheng's current research projects, which is primarily supported by National Heart, Lung, and Blood Institute.
1) Structure and function relationship of ADAMTS13 enzyme
2) Cofactor-dependent regulation of ADAMTS13 function
3) Single B cell Ig sequencing to identify human monoclonal antibodies from iTTP patients.
4) Mechanism underlying allosteric regulation and inhibition of ADAMTS13 activity
5) Animal models including zebrafish, mice, and rats for understanding the potential environmental triggers or genetic abnormalities in pathogenesis of iTTP.
The laboratory employs various cutting-edge technologies, including molecular cloning, PCR, protein engineering, expression, and purification, as well as microfluidic shear-based assay or intravital microscopic imaging to analyze thrombus formation, leukocyte rolling. Additionally, CRISP/Cas, single B cell Ig or RNA seq, bioinformatics, and CryoEM, etc. are employed to further understand the pathogenic mechanism of iTTP and other thrombotic disorders.
Current Research and Grants
- Novel Therapeutics for Acquired Thrombotic Thrombocytopenic Purpura, NHLBI, PI
- Zheng, L, Abdelgawwad, M., S, Zhang, D, Xu, L, Wei, S, Cao, W, Zheng, X., L. 2020. Histone-induced thrombotic thrombocytopenic purpura in adamts13 -/- zebrafish depends on von Willebrand factor.. Haematologica, 105 (4), 1107-1119
- Sui, J, Lu, R, Halkidis, K, Kocher, N., K, Cao, W, Marques, M., B, Zheng, X., L. 2020. Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura.. Journal of thrombosis and haemostasis : JTH
- Lu, R, Sui, J, Zheng, X., L. 2020. Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.. Blood advances, 4 (21), 5378-5388
- Cao, W, Cao, W, Zhang, W, Zheng, X., L, Zhang, X., F. 2020. Factor VIII binding affects the mechanical unraveling of the A2 domain of von Willebrand factor.. Journal of thrombosis and haemostasis : JTH, 18 (9), 2169-2176
- Basu, M., K, Massicano, F, Yu, L, Halkidis, K, Pillai, V, Cao, W, Zheng, L, Zheng, X., L. 2020. Exome Sequencing Identifies Abnormalities in Glycosylation and ANKRD36C in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura.. Thrombosis and haemostasis
- Zheng, L, Zhang, D, Cao, W, Song, W., C, Zheng, X., L. 2019. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.. Blood, 134 (13), 1095-1105
- Sui, J, Cao, W, Halkidis, K, Abdelgawwad, M., S, Kocher, N., K, Guillory, B, Williams, L., A, Gangaraju, R, Marques, M., B, Zheng, X., L. 2019. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.. Blood advances, 3 (24), 4177-4186
- McDaniel, J., K, Abdelgawwad, M., S, Hargett, A, Renfrow, M., B, Bdeir, K, Cao, W., J, Cines, D., B, Long, XL. 2019. Human Netrophil Peptide-1 Inhibits Thrombus Formation Under Arterial Flow via Its Terminal Free Cysteine Thiols. Journal of Thrombosis and Haemostasis, 17, 596-606
- Kumar, M., A, Cao, W, Pham, H., P, Raju, D, Nawalinski, K, Maloney-Wilensky, E, Schuster, J, Zheng, X., L. 2019. Relative Deficiency of Plasma A Disintegrin and Metalloprotease with Thrombospondin Type 1 Repeats 13 Activity and Elevation of Human Neutrophil Peptides in Patients with Traumatic Brain Injury.. Journal of neurotrauma, 36 (2), 222-229